# UK clinical experience up to 52 weeks with linaclotide for irritable bowel syndrome with constipation.

> PubMed lists PMID 30302125 in Therapeutic advances in gastroenterology as Journal Article, with publication-date metadata of 2018-10-03 (day precision). PeptideScanner associated the retained record with the identity slug linaclotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-30302125-linaclotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-09-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-30302125-linaclotide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-30302125-linaclotide-v1.json
- Content SHA-256: `48c2944606a5563dca1754d526408f498543bc30071e0717502e563174e18740`

## Claims and source pins

### Headline

UK clinical experience up to 52 weeks with linaclotide for irritable bowel syndrome with constipation. ([`pubmed-observation-pmid-30302125-2023-09-28-db7f66789558`](#source-pubmed-observation-pmid-30302125-2023-09-28-db7f66789558))

### Summary

PubMed lists PMID 30302125 in Therapeutic advances in gastroenterology as Journal Article, with publication-date metadata of 2018-10-03 (day precision). PeptideScanner associated the retained record with the identity slug linaclotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30302125-2023-09-28-db7f66789558`](#source-pubmed-observation-pmid-30302125-2023-09-28-db7f66789558))

### Paragraph 1

PubMed lists PMID 30302125 in Therapeutic advances in gastroenterology as Journal Article, with publication-date metadata of 2018-10-03 (day precision). PeptideScanner associated the retained record with the identity slug linaclotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30302125-2023-09-28-db7f66789558`](#source-pubmed-observation-pmid-30302125-2023-09-28-db7f66789558))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-30302125-2023-09-28-db7f66789558`](#source-pubmed-observation-pmid-30302125-2023-09-28-db7f66789558))

## Sources

<a id="source-pubmed-observation-pmid-30302125-2023-09-28-db7f66789558"></a>
- **UK clinical experience up to 52 weeks with linaclotide for irritable bowel syndrome with constipation. · retained source version 1:2023-09-28:current:db7f6678955830dcf979c2ada0c8b15fb36e6f01b20f62a92673fcc5d4070320** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/30302125/) (`pubmed-observation-pmid-30302125-2023-09-28-db7f66789558`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "UK clinical experience up to 52 weeks with linaclotide for irritable bowel syndrome with constipation." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-30302125-linaclotide-v1.json SHA-256: 48c2944606a5563dca1754d526408f498543bc30071e0717502e563174e18740.